Home / Stocks / Aurobindo Pharma Ltd
AUROPHARMA

Aurobindo Pharma Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,805.7

Change

+9.4 (0.52%)

Open

₹1,796.9

Prev. Close

₹1,796.3

Day High

₹1,805.7

Day Low

₹1,778.0

Volume Analysis

Traded

864,937

Delivered

554,001

Delivery %

64.05%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Trading within 3% of its 52-week high (₹1860.0)
  • •Strong operating margin (20.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year EPS growth (22.4%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,842.64 ₹1,824.17 ₹1,814.94 ₹1,796.47 ₹1,787.24 ₹1,768.77 ₹1,759.54
Fibonacci ₹1,824.17 ₹1,813.59 ₹1,807.05 ₹1,796.47 ₹1,785.89 ₹1,779.35 ₹1,768.77
Camarilla ₹1,813.32 ₹1,810.78 ₹1,808.24 ₹1,796.47 ₹1,803.16 ₹1,800.62 ₹1,798.08

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+51.36%

1 Week

-0.08%

1 Month

+14.37%

3 Months

+11.37%

6 Months

+23.38%

1 Year

+49.52%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹964.36

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

9.16%

Net margin 10.8% × asset turnover 0.54x × equity multiplier 1.57x

Company Overview

Sector

Healthcare

Market Cap

₹104,215 Cr

P/E (TTM)

25.7

ROE

10.1%

Book Value

₹685.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Aurobindo Pharma Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Growth (46/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹1860.0); strong operating margin (20.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

70/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

46

Valuation

51

Cash Flow

59

Corporate Governance

68

Momentum

94

Institutional Ownership

62

Business Quality

65

Risk & Volatility

89

Liquidity

89

From Screener.in

  • −Stock is trading at 2.61 times its book value
  • −The company has delivered a poor sales growth of 6.32% over past five years.
  • −Company has a low return on equity of 10.8% over last 3 years.
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 7,219 7,352 7,580 7,567 7,796 7,979 8,382 7,868 8,286 8,646 8,853 9,150 10,263
Expenses + 5,846 5,753 5,920 5,949 6,230 6,401 6,622 6,265 6,608 6,873 7,103 7,271 8,110
Operating Profit 1,373 1,599 1,660 1,618 1,566 1,578 1,760 1,603 1,678 1,773 1,750 1,880 2,153
OPM % 19.0% 22.0% 22.0% 21.0% 20.0% 20.0% 21.0% 20.0% 20.0% 21.0% 20.0% 21.0% 21.0%
Other Income + 188 163 14 221 136 159 135 107 122 123 117 224 168
Interest 68 76 89 111 113 118 115 98 95 93 98 102 102
Depreciation 418 423 354 404 382 419 444 406 429 465 479 487 531
Profit before tax 1,076 1,262 1,230 1,324 1,207 1,200 1,335 1,207 1,276 1,339 1,291 1,515 1,688
Tax % 30.0% 26.0% 26.0% 31.0% 32.0% 30.0% 32.0% 32.0% 34.0% 32.0% 29.0% 32.0% 33.0%
Net Profit + 752 940 907 918 817 846 903 824 848 910 921 1,032 1,124
EPS in Rs 13 16 16 16 14 15 16 14 15 16 16 18 20
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 26 15 17 10 8 9 11 4 6 8 6 16 24

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 12,103 13,772 14,910 16,463 19,564 23,099 24,775 23,455 24,855 29,002 31,724 33,653 36,913
Expenses + 9,524 10,579 11,469 12,691 15,612 18,249 19,497 19,060 21,148 23,176 25,164 26,783 29,357
Operating Profit 2,579 3,193 3,441 3,772 3,952 4,849 5,278 4,396 3,707 5,826 6,560 6,870 7,556
OPM % 21.0% 23.0% 23.0% 23.0% 20.0% 21.0% 21.0% 19.0% 15.0% 20.0% 21.0% 20.0% 20.0%
Other Income + 81 200 115 105 70 166 3,195 152 291 366 613 404 632
Interest 160 257 67 78 263 305 74 49 140 290 457 384 395
Depreciation 333 392 428 558 668 967 1,055 1,127 1,245 1,522 1,649 1,778 1,961
Profit before tax 2,168 2,744 3,061 3,241 3,091 3,743 7,344 3,373 2,612 4,380 5,066 5,112 5,832
Tax % 28.0% 26.0% 25.0% 25.0% 24.0% 24.0% 27.0% 22.0% 26.0% 28.0% 31.0% 31.0% —
Net Profit + 1,571 2,024 2,301 2,423 2,364 2,844 5,334 2,647 1,928 3,169 3,484 3,503 3,987
EPS in Rs 27 35 39 41 40 49 91 45 33 54 60 60 69
Dividend Payout % 8.0% 7.0% 6.0% 6.0% 6.0% 6.0% 4.0% 20.0% 23.0% 8.0% 0.0% 7.0% —
Sales growth 50 14 8 10 19 18 7 -5 6 17 9 6 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 5,127 7,229 9,313 11,622 13,832 16,766 21,871 24,517 26,781 29,784 32,595 37,833 39,342
Borrowings + 4,451 5,041 3,364 4,770 6,967 5,826 5,339 2,851 5,286 6,648 8,263 8,073 8,630
Other Liabilities + 3,303 3,568 3,464 4,492 5,414 6,113 6,147 6,211 7,379 8,227 8,566 12,232 13,725
Total Liabilities 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 39,505 44,717 49,482 58,196 61,754
Fixed Assets + 3,706 4,180 4,834 6,521 8,475 9,396 9,374 10,532 11,024 14,493 14,794 17,407 21,415
CWIP 420 848 1,458 1,583 1,668 1,986 3,062 3,747 5,390 3,869 4,900 5,214 3,487
Investments 20 123 246 312 360 555 591 997 543 372 252 1,051 354
Other Assets + 8,765 10,745 9,662 12,527 15,768 16,827 20,390 18,362 22,549 25,983 29,536 34,525 36,498
Total Assets 12,910 15,896 16,200 20,942 26,271 28,765 33,416 33,638 39,505 44,717 49,482 58,196 61,754
Equity Capital 29 59 59 59 59 59 59 59 59 59 58 58 58

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 1,237 1,420 3,279 1,955 1,651 4,381 3,329 5,016 2,387 2,435 3,925 5,526
Cash from Investing Activity + -1,017 -1,446 -1,787 -1,927 -2,904 -1,563 597 -3,211 -3,971 -4,242 -1,866 -2,630
Cash from Financing Activity + 93 365 -1,915 864 1,919 -1,947 -1,365 -2,969 1,814 800 120 -1,269
Net Cash Flow 313 340 -424 892 666 871 2,561 -1,164 230 -1,007 2,178 1,628
Free Cash Flow 491 -146 1,594 714 114 2,969 1,503 2,693 -323 -1,067 1,408 2,468
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 67 67 118 70 61 106 87 143 84 72 86 107

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 51.84% → 51.88%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 6.85% 6.87% 6.69% 6.45% 6.67% 6.61% 6.88% 6.37% 6.55% 7.08% 6.63% 6.29%
Promoters 51.84% 51.84% 51.8% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.82% 51.88% 51.88%
Government 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.03% 0.05% 0.05% 0.05%
FII 20.72% 18.01% 16.73% 16.59% 16.29% 15.33% 14.38% 14.21% 13.95% 15.24% 16.38% 17.41%
DII 20.6% 23.28% 24.77% 25.14% 25.21% 26.23% 26.93% 27.6% 27.66% 25.82% 25.05% 24.37%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Aurobindo Pharma Ltd (this stock) 104,215 25.7 2.64 10.1%
Mankind Pharma Limited 108,424 46.5 6.16 13.1%
Max Healthcare Ins Ltd 99,557 70.1 8.82 14.7%
Cipla Ltd 112,563 36.2 3.18 11.6%
Dr. Reddy S Laboratories 115,092 41.1 2.96 11.2%
Lupin Limited 89,994 16.0 3.75 28.7%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Aurobindo Pharma Ltd?

Frequently Asked Questions about Aurobindo Pharma Ltd

Community Sentiment

What are other investors saying about Aurobindo Pharma Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.